Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 2, 2008

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Melanoma
Interventions
DRUG

Decitabine

Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.

DRUG

Pegylated Interferon Alpha-2b

Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00791271 - Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | Biotech Hunter | Biotech Hunter